Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the results of recent clinical studies of antiangiogenic agents combined with platinum-based chemotherapies in patients with advanced non-small-cell lung cancer
- Describe the safety and efficacy of combining vascular endothelial growth factor and epidermal growth factor receptor inhibitors in the treatment of advanced non-small-cell lung cancer
- Recall optimal dosing and frequency of bevacizumab for the treatment of non-small-cell lung cancer
Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.